5th Street Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.99M Buy
18,911
+346
+2% +$46.8K 1.14% 24
2026
Q1
$2.37M Buy
18,565
+198
+1% +$24.7K 1.02% 24
2025
Q4
$2.24M Sell
18,367
-320
-2% -$36.7K 1.05% 23
2025
Q3
$1.87M Buy
18,687
+615
+3% +$55.4K 0.93% 22
2025
Q2
$1.5M Buy
18,072
+882
+5% +$70.4K 0.74% 26
2025
Q1
$1.39M Buy
+17,190
New +$1.54M 0.67% 27

Other funds holding XBI

5th Street Advisors's XBI Position: Q2 2026 in Review

5th Street Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 1.9% in Q2 2026, buying an estimated $46.8K and bringing the position to 18,911 shares worth $2.99M. The position accounts for 1.14% of the portfolio, ranked #24.

5th Street Advisors first reported a position in XBI in Q1 2025 and has held it in 6 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • 5th Street Advisors held 18,911 shares of State Street SPDR S&P Biotech ETF worth $2.99M as of Q2 2026.
  • 5th Street Advisors bought 346 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $46.8K.
  • State Street SPDR S&P Biotech ETF made up 1.14% of 5th Street Advisors's portfolio in Q2 2026, its #24 holding.
  • 5th Street Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2025 and has held it in 6 quarters since.
  • 933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on 5th Street Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.